TEL AVIV, Israel--(BUSINESS WIRE)--ChemomAb today announced the appointment of Dr. Stephen Squinto as the company’s chairman of the board.
In this role, Dr. Squinto will help guide the company as it continues the clinical development of its lead compound towards advanced clinical trials.
“Dr. Squinto has led numerous biotech and pharmaceutical firms and his vast experience will be invaluable to ensuring that the company continues to bring its lead candidate through clinical trials in several fibrotic indications,” said Dr. Adi Mor, CEO and CSO of ChemomAb.
Dr. Squinto is a Venture Partner with OrbiMed who brings over 25 years of biotechnology industry experience to ChemomAb. After completing both his undergraduate and doctoral work at Loyola College of Chicago, Dr. Squinto started his career at Regeneron Pharmaceuticals while holding two separate academic positions at Tulane and LSU’s Medical Schools. He was a co-founder of Alexion Pharmaceuticals, Inc. and served as their Executive Vice President, Chief Global Operations Officer and Global Head of Research and Development. His work has led to over 70 scientific papers in the fields of gene regulation, growth factor biology and gene transfer, and he is the recipient of numerous honors and awards from academic and professional organizations for his scientific work.
“I was drawn to ChemomAb because I believe the company has found a novel mechanism of action that plays an important role in fibrosis processes. It’s lead drug is showing promising results that will now be tested in clinical trials,” said Dr. Squinto. “The team has done an impressive job in advancing the company and I look forward to supporting their continued success.”
ChemomAb is a clinical stage biopharmaceutical company, specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of fibrotic-inflammatory disorders including NASH as well as orphan indications. The antibodies are designed to treat patients with fibrotic and inflammatory diseases through a novel dual mechanism of action that interferes with fibrosis processes directly as well as attenuates the inflammatory process that supports the fibrotic milieu and disease progression. The leading compound, CM-101, was selected after meticulous testing in a series of pre-clinical animal models simulating human disorders and has shown promising safety and efficacy as well as a novel mechanism of action.